

1 SUBMITTED 11 OCT 21
2 REVISION REQ. 8 DEC 21; REVISION RECD. 6 JAN 22
3 ACCEPTED 19 JAN 22
4 **ONLINE-FIRST: FEBRUARY 2022**
5 DOI: <https://doi.org/10.18295/squmj.2.2022.014>
6

7 Don't Miss the Target

8 **Ola Hamdani,¹ Buthaina Al-Yahyai,¹ *Edwin Stephen,² Ibrahim Abdelhady,²**
9 **Hanan Al-Mawaali,² Rashid Al-Sukaiti,³ Khalifa Al-Wahaibi²**

10
11 *¹Oman Medical Specialty Board, Muscat, Oman; Departments of ²Surgery and ³Radiology, Sultan*
12 *Qaboos University Hospital, Muscat, Oman.*

13 **Corresponding Author's e-mail: edwinmay2013@gmail.com*
14

15 A 27-year-old gentleman, with no diagnosed comorbidities, presented to the vascular surgery
16 clinic, referred as a case of lymphangioma, after an ultrasound was done elsewhere. He presented
17 with a history of a progressively enlarging left lateral arm swelling, that he noticed two years
18 earlier, when receiving an intramuscular injection for analgesia, following an injury to the leg,
19 while playing football. Examination revealed [Figure 1] hyper-pigmented spots, Cafe-au-lait
20 macules (CALMs), distributed over his body. The swelling was overlying the lateral aspect of
21 the left arm, measuring about 12 x 7 cm. It was non-tender and firm with limited mobility. There
22 were similar smaller swellings over his chest, back and other limbs. MRI was performed after a
23 clinical diagnosis of Neurofibromatosis [Type 1]. This revealed a classical appearance of
24 neurofibroma's known as the: Target sign, shown in Figure 2. Patient's consent was obtained
25 prior to taking and using his photos and images.
26

27 **Comment**

28 Neurofibromatosis is an autosomal dominant neurocutaneous disorder. It has two types:
29 Neurofibromatosis type I (NF-1) and neurofibromatosis type 2 (NF-2). NF -1 makes up about
30 96% of all cases. It affects 1 in 3000 individuals worldwide and presents with cutaneous and
31 non-cutaneous manifestations. Commonly, it presents with Café au lait spots, neurofibromas,

32 axillary or groin freckling and optic manifestations. Other complications of the disease includes
33 seizures, problems with digestion, psychological burdens and developmental delay including
34 delay in learning to walk and talk. NF-2 usually presents with schwannomas and meningiomas.^{1,3}
35 There are three varieties of neurofibroma's: Localized, diffuse and plexiform.

36
37 Classically, radiologists have recognized two types of neurofibroma: The discrete mass/nodular
38 form and the diffuse or plexiform variety.¹ On MRI, plexiform neurofibromas present with the
39 pathognomonic "target Sign" depicted as lesions with central hypo - intensity and surrounding
40 hyperintense rim on T2-weighted images, representing fibro collagenous and myxoid
41 components respectively. A "Reverse target sign", on T1-weighted images after IV gadolinium-
42 based contrast administration, is seen as central enhancement with peripheral hypo intensity.⁴
43 Venous malformations mimic the classical "target sign" seen in plexiform neurofibromas,
44 whereby the central hypointense focus represents a phlebolith in a dilated venous channel.

45
46 Phleboliths are also noted as a focal hyperintensity on gradient-recalled echo sequences. Other
47 MRI-differentiating features of venous malformations include a hyperintense, lobulated and
48 septated lesion on T2-weighted images & IV contrast enhancement of its cavernous section
49 without arteriovenous shunting on dynamic MR imaging.⁴ NF-1 with its various manifestations
50 is a clinical diagnosis and its management requires the involvement of a multidisciplinary team.
51 Patients are referred to surgeons to excise the neurofibroma when the patient is symptomatic
52 with pain, a recent increase in size, the tumor is resulting in a neurological deficit or has a high
53 risk of rupture and bleed. Plexiform neurofibromas, carries significant morbidity due to the way
54 it infiltrates surrounding structures, it's unpredictable growth and its potential to bleed.⁵

55 56 **Authors' Contribution**

57 ES conceptualized the manuscript. OH, BY, IA and RS performed the literature review. OH, BH,
58 IA, HM, RS and KW drafted the manuscript. ES revised the manuscript. All authors approved
59 the final version of the manuscript.

60 61 **References**


- 62 1. Rosalie E. Ferner, David H. Gutmann, Chapter 53 - Neurofibromatosis type 1 (NF1):
63 diagnosis and management, Handbook of Clinical Neurology. Said G, Krarup C, Volume 115,
64 2013, Pages 939-955, Ferner. Accessed on <Doi.org/10.1016/B978-0-444-52902-2.00053-9>
65
- 66 2. Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG, Upadhyaya M, Towers
67 R, Gleeson M, Steiger C, Kirby A. Guidelines for the diagnosis and management of individuals
68 with neurofibromatosis 1. Journal of medical genetics. 2007 Feb 1;44(2):81-8.
69
- 70 3. Grover, S. B., Kundra, R., Grover, H., Gupta, V., & Gupta, R. (2021). Imaging diagnosis of
71 plexiform neurofibroma-unravelling the confounding features: A report of two cases. *Radiology*
72 *case reports*, 16. Accessed on < doi.org/10.1016/j.radcr.2021.06.025>
73
- 74 4. O'Keefe P, Reid J, Morrison S, Vidimos A, DiFiore J. Unexpected diagnosis of superficial
75 neurofibroma in a lesion with imaging features of a vascular malformation. *Pediatric radiology*.
76 2005 Dec;35(12):1250-3.
77
- 78 5. Stephen E, Kariyattil R, Mittal A, Al-Azri F, Al-Wahaibi K. Spontaneous near fatal
79 hemorrhage neurofibromatosis type 1 of the scalp. *Oman Medical Journal*. 2020 Oct. Accessed
80 on <DOI 10.5001/omj.2022.02>

81
82
83



84
85
86

Figure 1: Café-au-lait macules, and multiple swellings in the arms.



87
88
89
90
91

Figure 2A: MRI image, left arm, showing localized lesion laterally (yellow arrow); with plexiform lesion medially (Green arrow); **2B:** MRI axial image, showing the Target sign (Orange arrow). The target sign refers to a central area with low signal intensity, surrounded by a high signal intensity and is sometimes referred to as a bull's eye sign.